

## Independent Medical Education Request for Proposals (RFP)

### Clinical Data Updates and Treatment Management Strategies in First-line ALK-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

#### Competitive Grant Program – Pfizer Internal Review Process

Date RFP Issued: August 26, 2024

## I. Eligibility

---

### Geographic Scope/Location of Project:

United States only

### Applicant Eligibility Criteria

- **Applicant organizations to this RFP must be based in the United States.**
- The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional organizations/medical societies; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement.
- Only organizations are eligible to receive grants, not individuals or physician-owned medical practices.
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- For projects offering continuing education credit in the United States, the requesting organization must be accredited.

## II. Requirements

---

### General Area of Interest for this RFP:

Projects that will be considered for Pfizer support will focus on increasing healthcare professional understanding and competence in one or more of the following areas:

- Increase understanding and importance of the latest clinical data updates relevant to the treatment of patients with metastatic ALK+ NSCLC.
- Address educational gaps in community oncology in diagnoses, treatment and management of patients with ALK+ NSCLC.
- Optimize ALK inhibitor-based treatment through proper management of adverse events through dose modifications and innovative strategies.
- Maximize therapy management strategies of ALK inhibitors through collaboration between experts in academic centers and community oncologists.
- Provide education directly to patients on the importance of appropriate biomarker testing.
- The role of the multi-disciplinary team (including pharmacist, nurse, and other allied health providers) collaboration and coordination of care in treatment management and monitoring during ALK inhibitor therapy.
- Management of neurocognitive adverse events in patients treated with oral oncolytic therapies.

Examples of educational formats that will be considered under this RFP include but are not limited to:

- Medical School and Fellowship Training curricula updates
- Testing and treatment algorithms and resources
- Interactive forum for sharing of real experiences (could be either peer-to-peer platforms for healthcare professionals or patient groups for patient education and interaction)
- On-agenda educational sessions during live conferences
- Multi-company supported, stand-alone symposia
- Expert interviews recorded at live conferences, conference coverage reviews
- Online articles, newsletter articles, training courses, webinars
- Social media posted & linked content
- Videos, podcasts, infographics, animations

*It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered.*

### Target Audience:

- Oncologists, oncology nurses and nurse practitioners, physician assistants, pharmacists and other healthcare professionals involved in the care and treatment of people with ALK+ metastatic NSCLC.
- Patients with ALK+ metastatic NSCLC and caregivers.

### Expected Approximate Monetary Range of Grant Applications:

- Individual projects requesting up to \$250,000 will be considered. The estimated total available budget related to this RFP is \$1,000,000.
- Award amounts include direct costs, institutional overhead costs (capped at 28% per Pfizer policy), and indirect costs.

### Key Dates:

- RFP release date: August 26, 2024
- Grant Application due date: October 14, 2024  
Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5).
- Anticipated Grant Award Notification Date: November 19, 2024
- Grants will be distributed following a fully executed agreement.
- Anticipated Approximate Project Start and End Dates: December 2024 to May 2026 (18 months preferred maximum length; projects may be shorter than 18 months)

### How to Submit:

Note: Please read this section carefully since applications submitted not following these instructions will not be accepted and will be cancelled.

- Please go to [www.cybergrants.com/pfizer/knowledge](http://www.cybergrants.com/pfizer/knowledge) and sign in. First-time users should click “Create your password”. [Note: there are individual portals for each grant application type. Please be sure to use the URL above.]
- Click the “Start A New Knowledge Gap Application” button.
- In the application:
  - For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP)
  - For the question “Are you replying to a Request for Proposal (RFP) as part of the Competitive Grant Program?” select Yes
- Select the following Competitive Grant Program Name: **2024 ONC US ALK+ Metastatic NSCLC IME**

- Select the following Primary Area of Interest: Oncology – Lung – KG
- Requirements for submission:  
Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field.
- If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page.

**IMPORTANT:** Be advised applications submitted after the due date will not be reviewed.

#### Questions:

- If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Don Rodriguez ([Don.Rodriguez@pfizer.com](mailto:Don.Rodriguez@pfizer.com)), with the subject line “2024 Clinical Data Updates and Treatment Management Strategies in First-line ALK-positive Metastatic NSCLC”

#### Grant Agreements:

- If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click [here](#) to view the core terms of the agreement.
- Under Pfizer’s competitive grant program, modifications to grant agreements will not be reviewed unless a genuine conflict exists as between applicable law and the terms of the relevant grant agreement. Applicant is encouraged to share the core terms with counsel for approval prior to submitting an application.
- Except where prohibited by applicable law and, in any case, subject to review by Pfizer Legal, payment of grant funding may only be paid to the grantee organization.
- This RFP is supported by Pfizer Inc. and, if approved, payment will be sent from the United States.

#### Review and Approval Process:

- Grant requests received in response to a general RFP are reviewed by Pfizer colleagues to make final grant decisions.

#### Mechanism by which Applicants will be Notified:

- All applicants will be notified via email by the dates noted above.
- Applicants may be asked for additional clarification during the review period.

#### References:

- NCCN Guidelines Version 7.2024 Non-Small Cell Lung Cancer
- Solomon, B. J., Liu, G., Felip, E., Mok, T. S. K., Soo, R. A., Mazieres, J., ... Bauer, T. M. (2024). Lorlatinib versus crizotinib in patients with advanced alk-positive non-small cell lung cancer: 5-year outcomes from the Phase III Crown Study. *Journal of Clinical Oncology*. doi:10.1200/jco.24.00581

## About Pfizer Global Medical Grants

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.

## Appendix

---

### General RFP Submission Requirements

Applications will be accepted via the online portal listed in the [How to Submit](#) section. Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. When uploading your Project Proposal please ensure it addresses the following sections:

#### Goals and Objectives

- Briefly state the overall goal of the project.
- List the objectives you plan to meet with your project, in terms of learning and expected outcomes.

#### Needs Assessment for the Project

- Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.

#### Target Audience

- Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.

#### Project Design and Methods

- Describe the planned project, the educational approach, and the way the planned methods address the established need.
- Describe any plans as to how the content will be assessed to ensure it is up-to-date over the education implementation and delivery lifecycle.

#### Innovation

- Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.

#### Evaluation and Outcomes

- In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.

#### Dissemination Plan

- Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the initial project. Describe how the project outcomes might be broadly disseminated.

#### Anticipated Project Timeline

- Provide an anticipated timeline for your project including project start/end dates.

## Additional Information

- If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.

## Organization Detail

- Describe the attributes of the institutions / organizations / associations that will support and facilitate the execution of the project and the leadership of the proposed project. Articulate the specific role of each partner in the proposed project.

## Budget Detail

- Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application.
- While estimating your budget please keep the following items in mind:
  - Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription).
  - Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer. Please [click here](#) for details. General organizational running costs such as legal fees, insurance, heating, and lighting etc. should be included in an Institutional Overhead (if required). These costs are not specific to a grant request and therefore, should not appear as line items in budgets. However, costs that are specific to the study (e.g., some countries require insurance to be taken out on a per-study basis for clinical research) would be acceptable to be included as line items.